ArticleDigestive diseases (Basel, Switzerland)2026
Eosinophilic Esophagitis as a Complex Th2 Inflammatory Disease: Results of a Prospective Long-Term Study in Children.
Article in Digestive diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PSMB8 stratifies therapy response in eosinophilic esophagitis.Clinical and experimental immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: While the eosinophilic esophagitis (EoE) has become the second most common disease entity causing esophageal dysfunction, there is currently a lack of data reporting on pediatric EoE from Germany. This monocentric longitudinal study seeks to fill this gap by investigating treatment success, atopic co-morbidities, and potential blood parameters in a real-world setting.
methodsThis study analyzed data on children with EoE (n = 50), gastroesophageal reflux disease (GERD, n = 13), and controls (n = 5). Evaluated characteristics included clinical manifestations, atopy, and treatment success during disease progress. We defined the primary endpoint as histological remission in all esophageal locations (proximal, mid, distal). Secondary endpoints were histological-clinical, histological-endoscopic, and histological-clinical-endoscopic remission.
resultsOf 50 patients (0.5-16.9 years), 26% (n = 13) responded to proton-pump inhibitors (PPI-R) and 74% (n = 37) needed other forms of treatment (PPI-NR). Atopic co-morbidities were observed in 46% (PPI-NR) and 23% (PPI-R). Primary PPI treatment resulted in histological remission in 13 patients (median: 2 [2;4.5] months); only one (8%) achieved complete endoscopic-clinical-histological remission. Thirty-two PPI-NRs (84%) reached histological remission after a median of 7 [4;11] months, but only eleven (34%) acquired complete histological-clinical-endoscopic remission. Absolute blood eosinophil count (AEC) was increased within active EoE (420 [250;550] cells/µL). It distinguished EoE from controls (cutoff 90 cells/µL, sensitivity/specificity: 95.7%/80%) and from GERD (180 cells/µL, 87.5%/66.7%). Eosinophilic cationic protein (ECP) differed between children with active EoE and controls (10 µg/L, 86.7%/100%).
conclusionsPatients' characteristics are comparable to those from other European countries. AEC and ECP were increased in EoE patients. Achieving complete remission required an intensified therapy regime. </p>.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.